Search

Your search keyword '"Rha, S. Y."' showing total 205 results
Start Over Author "Rha, S. Y."
205 results on '"Rha, S. Y."'

1. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Author

Grünwald, V., primary, Powles, T., additional, Eto, M., additional, Kopyltsov, E., additional, Rha, S. Y., additional, Porta, C., additional, Motzer, R., additional, Hutson, T. E., additional, Méndez-Vidal, M. J., additional, Hong, S. H., additional, Winquist, E., additional, Goh, J. C., additional, Maroto, P., additional, Buchler, T., additional, Takagi, T., additional, Burgents, J. E., additional, Perini, R., additional, He, C., additional, Okpara, C. E., additional, McKenzie, J., additional, and Choueiri, T. K., additional

Published
2024
Full Text
View/download PDF

3. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study

Author

Motzer, R., primary, Porta, C., additional, Alekseev, B., additional, Rha, S. Y., additional, Choueiri, T. K., additional, Mendez-Vidal, M. J., additional, Hong, S. H., additional, Kapoor, A., additional, Goh, J. C., additional, Eto, M., additional, Bennett, L., additional, Wang, J., additional, Pan, J. J., additional, Saretsky, T. L., additional, Perini, R. F., additional, He, C. S., additional, Mody, K., additional, and Cella, D., additional

Published
2022
Full Text
View/download PDF

5. Risk factors for delirium among patients with advanced cancer in palliative care: a multicenter, patient-based registry cohort in South Korea.

Author

LEE, S. W., JUNG, E. H., KIM, H. J., MIN, C., YOO, S. H., KIM, Y. J., RHA, S. Y., YON, D. K., and KANG, B.

Abstract

OBJECTIVE: Previous studies have comprehensively investigated the prevalence and various potential risk factors for delirium among patients with advanced cancer admitted to the acute palliative care unit (APCU). Our objective was to evaluate the comprehensive association between delirium and various risk factors among patients with advanced cancer in an acute palliative care setting using a patient-based multicenter registry cohort. PATIENTS AND METHODS: We performed a multicenter, patient-based registry cohort study collected in South Korea between January 1, 2019, and December 31, 2020. Delirium was identified using a medical record review based on the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. RESULTS: In total, 2,124 eligible patients with advanced cancer in the APCU met the inclusion criteria. There were 127 out of 2,124 patients (prevalence, 6.0%; 95% CI, 5.0 to 7.1) with delirium during admission. Delirium in patients with advanced cancer was associated with age >70 years (OR, 1.793; 95% CI, 1.246 to 2.581), male sex (OR, 1.675; 95% CI, 1.131 to 2.479), no chemotherapy during hospitalization (OR, 2.019; 95% CI, 1.236 to 3.298), hearing impairment (OR, 3.566; 95% CI, 1.176 to 10.810), underweight (OR, 1.826; 95% CI, 1.067 to 3.124), current use of opioid medication (OR, 1.942; 95% CI, 1.264 to 2.982), previous history of delirium (OR, 12.497; 95% CI, 6.920 to 22.568), and mental illness (OR, 2.333; 95% CI, 1.251 to 4.352). CONCLUSIONS: In a large-scale multicenter patient-based registry cohort, delirium was associated with old age, male sex, no chemotherapy during hospitalization, hearing impairment, underweight, current use of opioid medication, and a history of delirium and mental illness. Our findings suggest physicians should pay attention to delirium in patients with advanced cancer admitted to the APCU with the above risk factors. [ABSTRACT FROM AUTHOR]

Published
2023

7. Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC) : Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms

Author

Grünwald, Viktor, Hutson, T., Choueiri, T. K., Motzer, R., Rha, S. Y., Alyasova, A., Merchan, J., Gurney, H., Peer, A., Takagi, T., Porta, C., Powles, T., De Giorgi, U., Vaishampayan, U., Schmidinger, M., Glen, H., Rodriguez-Lopez, K., Xing, D., Dutta, L., and Eto, M.

Subjects
Medizin, ComputingMethodologies_GENERAL
Abstract

Poster-Abstract

Published
2021

24. Fourth-line therapy in metastatic renal cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC)

Author

Stukalin, I. Connor Wells, J. Fraccon, A. Pasini, F. Porta, C. Lalani, A.-K.A. Srinivas, S. Alex Bowman, I. Brugarolas, J. Lee, J.-L. Donskov, F. Beuselinck, B. Bamias, A. Rini, B.I. Sim, H.-W. Agarwal, N. Rha, S.-Y. Kanesvaran, R. Choueiri, T.K. Heng, D.Y.C.

Abstract

Background: Fourth-line therapy (4LT) in the treatment of metastatic renal cell carcinoma (mRCC) varies significantly due to the lack of data and recommendations to guide treatment decisions. Objective: To evaluate the use and efficacy of 4LT in mRCC patients. Methods: The International mRCC Database Consortium (IMDC) dataset was used to identify patients with mRCC treated with 4LT. This is a multicenter, retrospective cohort study. Overall survival (OS) and progression-free survival (PFS) were calculated using Kaplan-Meier curves. Patients were evaluated for overall response. The six prognostic variables included in the IMDC prognostic model were used to stratify patients into favorable-, intermediate- and poor-risk groups. Exploratory analyses were performed examining the elderly (>70 years old) and non-clear cell RCC subgroups. Proportional hazards regression modelling was performed adjusting these covariates by IMDC criteria measured at initiation of 4th line therapy. Results: 7498 patients were treated with first line targeted therapy and out of these 594 (7.9%) received 4LT. Everolimus was the most frequently used 4LT (16.8%). Sorafenib, axitinib, pazopanib, sunitinib and clinical trial drugs were also used in >10% of patients. The OS of patients on any 4LT was 12.8 months, with a PFS of 4.4 months. The overall response rate (ORR) was 13.7%. Favorable-risk patients using IMDC criteria (5%) displayed an OS of 23.1 months, intermediate-risk patients (66%) had an OS of 13.8 months and poor-risk patients (29%) had an OS of 7.8 (p < 0.0001) months. Age >70 years and non-clear cell histology did not impact OS. Our study is limited by its retrospective design. Conclusions: 4LT use appears to have activity in mRCC patients. The IMDC continues to be of prognostic value in the fourth-line setting for OS. This study helps to set a benchmark for response rate and survival for which clinical trials can plan sample size calculations and aim to improve upon. © 2018 - IOS Press and the authors. All rights reserved

Published
2018

25. Safety, anti-tumour activity, and biomarker results of the HER2-targeted bispecific antibody ZW25 in HER2-expressing solid tumours

Author

Oh, D.-Y., primary, Hamilton, E., additional, Hanna, D., additional, Beeram, M., additional, Lee, K.-W., additional, Kang, Y.-K., additional, Chaves, J., additional, Lee, J.-Y., additional, Goodwin, R., additional, Vaklavas, C., additional, Rha, S.-Y., additional, Elimova, E., additional, Mayordomo, J., additional, Ferrario, C., additional, Cobleigh, M., additional, Fortenberry, A., additional, Rowse, G., additional, Gray, T., additional, Lai, R., additional, and Meric Bernstam, F., additional

Published
2019
Full Text
View/download PDF

26. Body mass index and metastatic renal cell carcinoma: Clinical and biological correlations

Author

Albiges, L. Ari Hakimi, A. Xie, W. McKay, R.R. Simantov, R. Lin, X. Lee, J.-L. Rini, B.I. Srinivas, S. Bjarnason, G.A. Ernst, S. Wood, L.A. Vaishamayan, U.N. Rha, S.-Y. Agarwal, N. Yuasa, T. Pal, S.K. Bamias, A. Zabor, E.C. Skanderup, A.J. Furberg, H. Fay, A.P. De Velasco, G. Preston, M.A. Wilson, K.M. Cho, E. McDermott, D.F. Signoretti, S. Heng, D.Y.C. Choueiri, T.K.

Abstract

Purpose: Obesity is an established risk factor for clear cell renal cell carcinoma (RCC); however, some reports suggest that RCC developing in obese patients may be more indolent. We investigated the clinical and biologic effect of body mass index (BMI) on treatment outcomes in patients with metastatic RCC. Methods: The impact of BMI (high BMI: ≥ 25 kg/m2 v low BMI:, 25 kg/m2) on overall survival (OS) and treatment outcome with targeted therapy was investigated in 1,975 patients from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and in an external validation cohort of 4,657 patients. Gene expression profiling focusing on fatty acid metabolism pathway, in The Cancer Genome Atlas data set, and immunohistochemistry staining for fatty acid synthase (FASN) were also investigated. Cox regression was undertaken to estimate the association of BMI with OS, adjusted for the IMDC prognostic factors. Results: In the IMDC cohort, median OS was 25.6 months (95% CI, 23.2 to 28.6) in patients with high BMI versus 17.1 months (95% CI, 15.5 to 18.5) in patients with low BMI (adjusted hazard ratio, 0.84; 95% CI, 0.73 to 0.95). In the validation cohort, high BMI was associated with improved OS (adjusted hazard ratio, 0.83; 95% CI, 0.74 to 0.93; medians: 23.4 months [95% CI, 21.9 to 25.3 months] v 14.5 months [95% CI, 13.8 to 15.9 months], respectively). In The Cancer Genome Atlas data set (n = 61), FASN gene expression inversely correlated with BMI (P =.034), and OS was longer in the low FASN expression group (medians: 36.8 v 15.0 months; P =.002). FASN immunohistochemistry positivity was more frequently detected in IMDC poor (48%) and intermediate (34%) risk groups than in the favorable risk group (17%; P-trend =.015). Conclusion: High BMI is a prognostic factor for improved survival and progression-free survival in patients with metastatic RCC treated with targeted therapy. Underlying biology suggests a role for the FASN pathway. © 2016 by American Society of Clinical Oncology.

Published
2016

28. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy

Author

Grünwald V., Karakiewicz P. . I, Bavbek S. . E, Miller K., Machiels J. P., Lee S. H., Larkin J., Bono P., Rha S. Y., Castellano D., Blank C. U., Knox J. J., Hawkins R., Anak O., Rosamilia M., Booth J., Pirotta N., Bodrogi I., REACT Study Group, included, DE PLACIDO, SABINO, Grünwald, V., Karakiewicz, P. . I., Bavbek, S. . E., Miller, K., Machiels, J. P., Lee, S. H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., REACT Study, Group, Included, and DE PLACIDO, Sabino

Published
2012

30. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy

Author

Kroeger, N. Choueiri, T.K. Lee, J.-L. Bjarnason, G.A. Knox, J.J. Mackenzie, M.J. Wood, L. Srinivas, S. Vaishamayan, U.N. Rha, S.-Y. Pal, S.K. Yuasa, T. Donskov, F. Agarwal, N. Tan, M.-H. Bamias, A. Kollmannsberger, C.K. North, S.A. Rini, B.I. Heng, D.Y.C.

Abstract

Background A subset of primarily localized renal cell carcinoma (RCC) patients will experience disease recurrence ≤5 yr after initial nephrectomy. Objective To characterize the clinical outcome of patients with late recurrence beyond 5 yr. Design, setting, and participants Patients with metastatic RCC (mRCC) treated with targeted therapy were retrospectively characterized according to time to relapse. Relapse was defined as the diagnosis of recurrent metastatic disease >3 mo after initial curative-intent nephrectomy. Patients with synchronous metastatic disease at presentation were excluded. Patients were classified as early relapsers (ERs) if they recurred within 5 yr; late relapsers (LRs) recurred after 5 yr. Outcome measurements and statistical analysis Demographics were compared with the Student t test, the chi-square test, or the Fisher exact test. The survival time was estimated with the Kaplan-Meier method, and associations with survival outcome were assessed with univariable and multivariable Cox regression analyses. Results and limitations Among 1210 mRCC patients treated with targeted therapy after surgery for localized disease, 897 (74%) relapsed within the first 5 yr and 313 (26%) (range: 5-35 yr) after 5 yr. LRs presented with younger age (p < 0.0001), fewer with sarcomatoid features (p < 0.0001), more clear cell histology (p = 0.001), and lower Fuhrman grade (p < 0.0001). Overall objective response rates to targeted therapy were better in LRs versus ERs (31.8% vs 26.5%; p = 0.004). LRs had significantly longer progression-free survival (10.7 mo vs 8.5 mo; p = 0.005) and overall survival (OS; 34.0 mo vs 27.4 mo; p = 0.004). The study is limited by its retrospective design, noncentralized imaging and pathology review, missing information on metastatectomy, and nonstandardized follow-up protocols. Conclusions A quarter of patients who eventually developed metastatic disease and were treated with targeted therapy relapsed over 5 yr from initial nephrectomy. LRs have more favorable prognostic features and consequently better treatment response and OS. © 2013 European Association of Urology.

Published
2014

33. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC

Author

Ko, J J, primary, Choueiri, T K, additional, Rini, B I, additional, Lee, J-L, additional, Kroeger, N, additional, Srinivas, S, additional, Harshman, L C, additional, Knox, J J, additional, Bjarnason, G A, additional, MacKenzie, M J, additional, Wood, L, additional, Vaishampayan, U N, additional, Agarwal, N, additional, Pal, S K, additional, Tan, M-H, additional, Rha, S Y, additional, Yuasa, T, additional, Donskov, F, additional, Bamias, A, additional, and Heng, D Y C, additional

Published
2014
Full Text
View/download PDF

39. Use of MTHFR A1298C polymorphism to predict response in a phase II international clinical trial of patients with advanced gastric (GC) or gastroesophageal junction (GEJ) adenocarcinoma treated with first-line lapatinib plus capecitabine.

Author

Labonte, M. J., primary, Yang, D., additional, Zhang, W., additional, Wilson, P. M., additional, Gerger, A., additional, Bohanes, P. O., additional, Ning, Y., additional, Benhaim, L., additional, El-Khoueiry, R., additional, Nagarwala, Y. M., additional, Kemner, A. M., additional, Pishvaian, M. J., additional, Hsieh, R. K., additional, Gladkov, O., additional, Urba, S., additional, Rha, S. Y., additional, Sakaeva, D., additional, Iqbal, S., additional, El-Khoueiry, A. B., additional, and Lenz, H., additional

Published
2011
Full Text
View/download PDF

48. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil–based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.

Author

Kim, Y. H., primary, Sasaki, Y., additional, Lee, K. H., additional, Rha, S. Y., additional, Park, S., additional, Boku, N., additional, Komatsu, Y., additional, Kim, T., additional, Kim, S., additional, and Sakata, Y., additional

Published
2011
Full Text
View/download PDF

49. Kidney Cancer Working Group Report

Author

Naito, S., primary, Tomita, Y., additional, Rha, S. Y., additional, Uemura, H., additional, Oya, M., additional, Song, H. Z., additional, Zhong, L. H., additional, and Wahid, M. I. B. A., additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results